BAMS
UBIO

Bellevue Asset Management (Switzerland)’s Proshares UltraPro NASDAQ Biotechnology UBIO Stock Holding History

Bellevue Asset Management (Switzerland)’s Portfolio UBIO Stock Details UBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-7,000
Closed -$2.04M – 137
2015
Q3 		$2.04M Buy
+7,000
New +$568K 0.33% 84

Other funds holding UBIO

VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 19.31% 1-Year Est. Return
CT
CMT Trading Chicago, Illinois $22.4M AUM 78.15% 1-Year Est. Return
CG
Cutler Group San Francisco, California $307M AUM 45.11% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bellevue Asset Management (Switzerland)'s UBIO Position: Q4 2015 in Review

Bellevue Asset Management (Switzerland) sold out of Proshares UltraPro NASDAQ Biotechnology (UBIO) in Q4 2015, closing a stake of 7,000 shares — an estimated $2.04M sold.

Bellevue Asset Management (Switzerland) first reported a position in UBIO in Q3 2015 and held it in 1 quarter. The position peaked at $2.04M in Q3 2015. 8 funds tracked by Wall St. Rank hold UBIO as of Q4 2015.

  • Bellevue Asset Management (Switzerland) reported no remaining Proshares UltraPro NASDAQ Biotechnology position as of Q4 2015 after selling out during the quarter.
  • Bellevue Asset Management (Switzerland) sold 7,000 Proshares UltraPro NASDAQ Biotechnology shares in Q4 2015, an estimated $2.04M.
  • Bellevue Asset Management (Switzerland) first reported a position in Proshares UltraPro NASDAQ Biotechnology in Q3 2015 and held it in 1 quarter.
  • Bellevue Asset Management (Switzerland)'s Proshares UltraPro NASDAQ Biotechnology position peaked at $2.04M in Q3 2015.
  • 8 funds tracked by Wall St. Rank held Proshares UltraPro NASDAQ Biotechnology as of Q4 2015.

Based on Bellevue Asset Management (Switzerland)'s 13F filing for Q4 2015, filed 12 Feb 2016.